Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O95866

UPID:
G6B_HUMAN

ALTERNATIVE NAMES:
Protein G6b

ALTERNATIVE UPACC:
O95866; A2BEZ1; A2BEZ2; A2BEZ3; A2BEZ4; A2BEZ5; B0UXC4; B0UXC7; B0UXC8; B0V024; B0V026; Q14CK2; Q96A86; Q96A87; Q96A88; Q96A89; Q96A90; Q96A91

BACKGROUND:
The Megakaryocyte and platelet inhibitory receptor G6b, or Protein G6b, is essential for the regulation of hematopoietic lineage differentiation and platelet function. It uniquely contains both a transmembrane region and 2 ITIMs, distinguishing it as the inhibitory counterpart to other isoforms. Through inhibiting the signaling of CLEC1B and GP6:FcRgamma, it plays a crucial role in preventing overactive platelet aggregation and activation in a calcium-independent manner.

THERAPEUTIC SIGNIFICANCE:
Protein G6b's involvement in diseases such as thrombocytopenia, anemia, and myelofibrosis highlights its potential as a target for therapeutic intervention. Understanding the role of Protein G6b could open doors to potential therapeutic strategies, providing a new avenue for treating these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.